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Society for Vascular Surgery Vascular Registry
evaluation of stent cell design on carotid artery
stenting outcomes
Jeffrey Jim, MD,a Brian G. Rubin, MD,a Gregg S. Landis, MD,b Christopher T. Kenwood, MS,c
Flora S. Siami, MPH,c and Gregorio A. Sicard, MD,a and the SVS Outcomes Committee,* St. Louis, Mo;
Flushing, NY; and Watertown, Mass
Objective: The Society for Vascular Surgery (SVS) Vascular Registry (VR) collects data on outcomes of carotid
endarterectomy and carotid artery stenting (CAS). The purpose of this study was to evaluate the impact of open vs closed
cell stent design on the in-hospital and 30-day outcome of CAS.
Methods: The VR collects provider-reported data on patients using a Web-based database. Data were analyzed both
in-hospital and at 30 days postprocedure. The primary outcome is combined death/stroke/myocardial infarction (MI).
Results: As of October 14, 2009, there were 4337 CAS with discharge data and 2397 with 30-day data. Open cell stents
(OPEN) were used in 3451 patients (79.6%), and closed cell stents (CLOSED) were used in 866 patients (20.4%).
Baseline demographics showed no differences in age, gender, race, and ethnicity. However, the OPEN group had more
patients with atherosclerosis (74.5% vs 67.4%; P .0003) as the etiology of carotid artery disease. The OPEN group also
had a higher prevalence of preprocedural stroke (25.8% vs 21.4%; P  .0079), chronic obstructive pulmonary disease
(COPD; 21.0% vs 17.6%; P  .0277), cardiac arrhythmia (14.7% vs 11.4%; P  .0108), valvular heart disease (7.4% vs
3.7%; P < .0001), peripheral vascular disease (PVD; 40.0% vs 35.3%; P  .0109), and smoking history (59.0% vs 54.1%;
P .0085). There are no statistically significant differences in the in-hospital or 30-day outcomes between the OPEN and
CLOSED patients. Further subgroup analyses demonstrated symptomatic patients had a higher event rate than the
asymptomatic cohort in both the OPEN and CLOSED groups. Among symptomatic patients, the OPEN patients had a
lower (0.43% vs 1.41%; P  .0349) rate of in-hospital mortality with no difference in stroke or transient ischemic attack
(TIA). There were no differences in 30-day event rates. In asymptomatic patients, there were also no statistically
significant differences between the OPEN and CLOSED groups. After risk adjustment, there remained no statistically
significant differences between groups of the primary endpoint (death/stroke/MI) during in-hospital or 30 days.
Conclusion: In-hospital and 30-day outcomes after CAS were not significantly influenced by stent cell design. Symptom-
atic patients had higher adverse event rates compared to the asymptomatic cohort. As there is no current evidence of
differential outcome between the use of open and closed cell stents, physicians should continue to use approved stent
platforms based on criteria other than stent cell design. (J Vasc Surg 2011;54:71-9.)
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MStroke is the third leading cause of death and the
leading cause of serious long-term disability in the United
States.1,2 While carotid endarterectomy (CEA) has been
established as an effective means for treating carotid artery
disease, there are conflicting reports on the safety and
efficacy of carotid artery stenting (CAS).3,4 Furthermore,
carotid stents of different structural designs are available.
“Open cell” and “closed cell” stent designs differ not only
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doi:10.1016/j.jvs.2010.12.054n how the stent struts are connected, they also have a range of
ree cell area between the metal scaffolding (Table I).5 Using
ata from a multicenter European CAS registry, Bosiers et
l5 reported on the potential variation in the CAS complica-
ion rates according to stent type, free cell area, and cell design.
owever, a more recent series reported by Schillinger et al6
ould not support the superiority of a specific stent cell design
ith respect to outcomes. The influence of stent cell design on
AS outcomes thus remains unclear.
The Society for Vascular Surgery (SVS) Vascular Registry
VR) on carotid procedures was developed to collect long-
erm outcomes on patients treated with CAS and CEA.7 As the
rst societal registry to enroll patients with CAS and CEA,
he VR is the largest published database of CAS procedures in
heUnited States. The purpose of this article was to utilize the
VS-VR to evaluate stent cell design on CAS outcomes. The
n-hospital (procedure and predischarge) and 30-day out-
omes of CAS in patients treated with open cell stents (OPEN)
nd closed cell stents (CLOSED) are described.
ETHODS
VR data are reported by providers through Web-based
lectronic data capture. The measurement schedule in-
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July 201172 Jim et alcludes baseline (preoperative) information such as patient
demographics, medical history, carotid symptom status,
preprocedural diagnostic imaging and laboratory, proce-
dural information, including clinical utility, procedural and
predischarge complications; and follow-up information
such as postprocedure mortality, stroke, myocardial infarc-
tion (MI), and other morbidity. All data entered into the
VR are fully compliant with the Health Insurance Portabil-
ity and Accountability Act regulations and are auditable. All
data reports and analyses performed included only deiden-
tified and aggregated data.
New England Research Institutes (NERI, Watertown,
Mass) maintains the online database. Funding for the ad-
ministration and database management of the VR has been
provided by the SVS (Chicago, Ill).
Outcomes. The primary outcome measure is a com-
posite of the incidence of death, stroke, and MI. Stroke is
defined as any nonconvulsive, focal neurologic deficit of
abrupt onset persisting more than 24 hours. The ischemic
event must correspond to a vascular territory. An MI is
classified as either a Q-wave MI in which one of the
following criterion is required: (1) chest pain or other acute
symptoms consistent with myocardial ischemia and new
pathologic Q waves in two or more contiguous electrocar-
diogram (ECG) leads; or (2) new pathologic Q waves in
two or more contiguous ECG leads and elevation of cardiac
enzymes; or non-Q-wave MI, which is defined as CK ratio
2 and CK-MB 1 in the absence of new, pathologic Q
waves. In addition, although not considered specific out-
comes but of interest, transient ischemic attack (TIA) and
amaurosis fugax (or transient monocular blindness [TMB])
are also reported. Analysis of the 30-day outcomes were
based on only those patients who had at least a 30-day
follow-up visit (16 days) or who experienced an endpoint
(death, stroke, or MI) within 30 days of treatment.
Procedural success data were also collected. A CAS
procedure was deemed successful when all of its compo-
nents were completed without the need for conversion to
CEA, or its abandonment before completion, and 30%
residual stenosis achieved postprocedure.
Statistical methods. Tests of statistical significance
Table I. Types of stents used in patients with carotid
artery stenting
Design Manufacturer’s name
Free cell area
(mm2)
Closed cell Wallstent (Boston Scientific, Natick,
Mass)
1.08 mm2
X-act (Abbott Vascular Devices,
Redwood City, Calif)
2.74 mm2
NexStent (Endotex, Cupertino, Calif) 4.07 mm2
Open cell Precise (Cordis, Miami Lakes, Fla) 5.89 mm2
Exponent (Medtronic, Santa Rosa,
Calif)
6.51 mm2
Protégé (eV3, Plymouth, Minn) 10.71 mm2
Acculink (Guidant, Santa Clara, Calif) 11.48 mm2
As reported in Bosiers et al.5were conducted with 2 or Fisher exact tests for categorical 8ariables and analysis of variance (ANOVA) for continuous
ariables. Descriptive statistics are listed as mean  SD for
ontinuous variables and percent (frequency) for categori-
al variables. Subset analyses were performed using the
wo-tailed t test for continuous variables and the 2 or
isher exact test, as necessary, for discrete/categorical data.
nadjusted and adjusted odds ratios were used to compare
he primary outcomes across treatment groups. Odds ratios
ere adjusted for any significant baseline factors using
ogistic regression model. Differences were considered sig-
ificant if P .05. All statistical analyses were performed by
ERI using SAS Statistical Software (Cary, NC).
ESULTS
For the purpose of this report, data collected in the VR
rom the beginning of electronic data entry on July 11,
005, to October 14, 2009, were analyzed. There were
337 patients who had CAS with procedural and dis-
harge data, with 3451 patients (79.6%) in the OPEN
roup. The distribution of stents used can be found in the
ig. The 30-day cohort contained 2322 patients who had
AS with in-hospital and 30-day outcomes for analyses, of
hich 1775 patients (76.4%) were in the OPEN group.
Patient characteristics can be found in Table II. While
he two groups had similar age, race, and ethnicity, the
PEN group had fewer male patients that almost reached
tatistical significance (60.4% vs 64.0%; P  .0534). The
PEN group had more patients with atherosclerosis
74.5% vs 67.4%; P  .0003) as the etiology of carotid
rtery disease. The OPEN group also had a higher preva-
ence of stroke (25.8% vs 21.4%; P  .0079), chronic
bstructive pulmonary disease (COPD; 21.0% vs 17.6%;
 .0277), cardiac arrhythmia (14.7% vs 11.4%; P 
0108), valvular heart disease (7.4% vs 3.7%; P  .0001),
eripheral vascular disease (PVD; 40.0% vs 35.3%; P 
0109), and smoking history (59.0% vs 54.1%; P .0085).
here was no statistically significant difference in symptom-
tology (47.3% OPEN vs 48.2% CLOSED). The degree of
tenosis by contrast angiography was slightly higher and
tatistically significant in the CLOSED group (86.51% vs
ig. Distribution of stents used in carotid artery stenting (CAS)
atients.5.75%; P  .0212), but the overall amount of patients
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Volume 54, Number 1 Jim et al 73with stenosis 80% or contralateral stenosis 70% were
similar between the two groups. While the OPEN group
was associated with a lower use of embolic protection
(97.1% vs 98.5%; P .0133), the number of stents used per
patient was similar.
In-hospital outcomes. There were no statistically sig-
nificant differences between the in-hospital adverse event
Table II. Baseline demographics, disease etiology, medica
stenting by stent design
OPEN
Age (year, range) 71.01
Gender (male %) 60.4%
Race (white %) 92.1%
Ethnicity (Hispanic %) 5.1%
Carotid disease etiology
Atherosclerosis 74.5%
Dissection 0.6%
Fibromuscular dysplasia 0.2%
Radiation 4.0%
Trauma 0.1%
Restenosis 20.0%
Other 0.7%
Medical history
Coronary artery disease 61.1%
Myocardial infarction 21.5%
Valvular heart disease 7.4%
Cardiac arrhythmia 14.7%
Congestive heart failure 14.6%
Hypertension 82.4%
Diabetes 33.9%
Transient ischemic attack 22.6%
Stroke 25.8%
COPD 21.0%
Chronic renal failure 3.7%
Amaurosis fugax (TMB) 6.7%
Peripheral vascular disease 40.0%
Gastrointestinal ulcer/bleeding 3.9%
Current or past smoker 59.0%
Cancer 16.5%
Coagulopathy 0.8%
ASA grade
2 89.0%
2 11.0%
NYHA Scale
3 88.6%
3 11.4%
Antiplatelet use 97.0%
Carotid evaluation
Carotid symptomatology (% symptomatic) 47.3%
Baseline stenosis % (mean, range) 85.75
Stenosis 80% 64.3%
Baseline ultrasound 80% 76.2%
Contralateral stenosis 70% 25.9%
Use of embolic protection 97.1%
Number of stents
1 93.6%
2 5.9%
3 0.4%
4 0.1%
ASA, American Society of Anesthesiology; CLOSED, closed cell stent; COP
OPEN, open cell stent; TMB, transient monocular blindness.
P values for age and baseline stenosis percentage were found using t test. P va
exact tests.rates for the OPEN and CLOSED groups (Table III). towever, in general, the OPEN group had lower event
ates, such as stroke (1.85% vs 2.14%) and the primary
utcome of combined death/stroke/MI (2.46% vs 3.16%).
fter adjusting for significant baseline factors such as etiol-
gy (atherosclerosis), valvular heart disease, cardiac ar-
hythmia, stroke, COPD, PVD, smoking status, percent
aseline stenosis, and use of embolic protection (Table IV),
ory, and carotid evaluation of patients with carotid artery
3451) CLOSED (n  886) P value
6) 71.25 (37-95) .5172
/3451) 64.0% (567/886) .0534
/3451) 93.9% (832/886) .0743
3451) 3.8% (34/886) .1352
/3451) 67.4% (597/886) .0003
3451) 0.2% (2/886)
451) 0.2% (2/886)
3451) 4.2% (37/886)
451) 0.0% (0/886)
3451) 27.3% (242/886)
3451) 0.7% (6/886)
/3451) 60.3% (534/886) .6714
3451) 22.3% (198/886) .5833
3451) 3.7% (33/886) .0001
3451) 11.4% (101/886) .0108
3451) 12.2% (108/886) .0661
/3451) 82.2% (728/886) .8823
/3451) 34.8% (308/886) .6622
3451) 22.5% (199/886) .9641
3451) 21.4% (190/886) .0079
3451) 17.6% (156/886) .0277
3451) 3.5% (31/886) .8413
3451) 6.8% (60/886) .9402
/3451) 35.3% (313/886) .0109
3451) 2.8% (25/886) .1344
/3451) 54.1% (479/886) .0085
3451) 16.9% (150/886) .8003
3451) 0.7% (6/886) 1.0000
/3451) 89.4% (792/886) .7631
3451) 10.6% (94/886)
/3451) 90.5% (802/886) .1046
3451) 9.5% (84/886)
/3451) 96.7% (857/886) .7440
/3451) 48.2% (427/886) .6510
0) 86.51 (40-100) .0212
/3451) 65.5% (574/886) .5273
/3451) 78.8% (617/886) .1397
3451) 26.3% (204/886) .8178
/3451) 98.5% (873/886) .0133
/3451) 94.5% (837/886) .3766
3451) 4.9% (43/886)
451) 0.7% (6/886)
51) 0.0% (0/886)
onic obstructive pulmonary disease; NYHA, New York Heart Association;
etiology was found using 2 test. all other P values were found using Fisherl hist
(n 
(23-9
(2084
(3178
(175/
(2570
(21/
(6/3
(139/
(3/3
(689/
(23/
(2107
(741/
(256/
(509/
(504/
(2843
(1171
(780/
(890/
(723/
(128/
(232/
(1381
(135/
(2036
(571/
(27/
(3071
(380/
(3057
(394/
(3346
(1633
(0-10
(2209
(2230
(752/
(3350
(3231
(204/
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D, chrhe OPEN group had a statistically significant lower rate of
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July 201174 Jim et alcombined death/stroke/TIA (odds ratio [OR], 0.674;
95% confidence interval [CI], 0.460-0.987; P  .0427).
However, there remained no statistically significant differ-
ences in the rates of death, stroke, MI, or combined pri-
mary endpoint.
In comparing symptomatology (Table V), there was a
statistically significant difference with an increase in the
incidence of stroke for symptomatic patients in both
groups. In the OPEN group, symptomatic patients had a
higher incidence of stroke (2.51% vs 1.27%; P .0077) and
combined death/stroke/MI (3.18% vs 1.82%; P .0111).
In the CLOSED cohort, symptomatic patients also had a
higher incidence of stroke (3.51% vs 0.87%; P .0091), as
well as combined death/stroke/MI (5.15% vs 1.31%; P 
.0016) and combined death/stroke/TIA rates (6.09% vs
2.61%; P .0124). When comparing symptomatic patients
by stent design (Table VI), the OPEN patients had a
statistically significant lower incidence of mortality (0.43%
vs 1.41%; P  .0349), but the difference in stroke rate was
not statistically significant (2.51% vs 3.51%), nor was the
difference in combined death/stroke/MI rate (3.18% vs
5.15%; P  .0577). In asymptomatic patients (Table VI),
there were no statistically significant differences for the
in-hospital outcomes between the OPEN and CLOSED
groups.
Thirty-day outcomes. Similar to the in-hospital out-
comes, there were no statistically significant differences
between the 30-day adverse event rates for the OPEN and
CLOSE groups (Table VII). However, in contrast to the
in-hospital findings, there is a reversal with a higher inci-
dence of stroke in the OPEN group (2.54% vs 1.65%). The
primary outcome of combined death/stroke/MI was
4.11% in the OPEN group and 3.66% in the CLOSED
group. After adjusting for baseline risk factors (Table VIII),
there were no statistically significant differences in the event
rates between the two groups.
When comparing symptomatology (Table IX) in the
OPEN group, there was a statistically significant difference
with an increase in the incidence of stroke (3.64% vs 1.63%;
Table III. In-hospital outcomes in OPEN versus
CLOSED patients
In-hospital outcomes
OPEN
(n  3451)
n (%)
CLOSED
(n  886)
n (%) P value
Death, stroke, or MI 85 (2.46) 28 (3.16) .2386
Death, stroke, or TIA 111 (3.22) 38 (4.29) .1213
Mortality 18 (0.52) 8 (0.90) .2192
Stroke 64 (1.85) 19 (2.14) .5825
MI 15 (0.43) 5 (0.56) .5816
TIA 36 (1.04) 14 (1.58) .2146
TMB 7 (0.20) 3 (0.34) .4366
CLOSED, Closed cell stent; MI, myocardial infarction; OPEN, open cell
stent; TIA, transient ischemic attack; TMB, transient monocular blindness.
P values were based on Fisher exact test. Outcomes are defined as any event
intraoperatively or predischarge. Rates are per patient.P  .0093) and TIA (2.39% vs 0.92%; P  .0200) for tymptomatic patients compared with asymptomatic pa-
ients. This led to higher rates of combined death/
troke/MI (5.28% vs 3.17%; P  .0302) and combined
eath/stroke/TIA (6.91% vs 3.78%; P  .0035). There
ere no statistically significant differences in outcomes
etween symptomatic and asymptomatic cohorts for the
LOSED group. When comparing symptomatic patients
y stent design (Table X), there were no statistically signif-
cant differences in outcomes. However, it is important to
oint out that in the OPEN group, there was a higher
ncidence of stroke (3.64% vs 1.89%) and combined death/
troke/MI (5.28% vs 4.53%) compared with the CLOSED
roup. In asymptomatic patients (Table X), there were also
o statistically significant differences between the OPEN
nd CLOSED groups. The primary endpoint of combined
eath/stroke/MI was 3.17% for OPEN patients and 2.84%
or CLOSED patients.
Secondary outcomes. Secondary outcomes are shown
n Table XI. The OPEN group had 100% technical success,
hile the CLOSED group had two technical failures
99.8% success; P  .0417). Patients in the OPEN group
ere more likely to have developed intraprocedural spasm
equiring treatment (2.1% vs 0.3%; P  .0001) and hypo-
ension requiring treatment (6.9% vs 3.7%; P  .0003).
ISCUSSION
Since its introduction in the 1990s, CAS offers an
lternative to CEA in the treatment of carotid artery steno-
is. Despite large randomized controlled trials, the safety
nd efficacy of CAS compared to CEA remain uncertain.3,4
everal patient-specific factors have been shown to be asso-
iated with poor CAS outcomes. These include advanced
atient age, extensive calcification of the aortic arch, and
resence of an internal carotid artery thrombus. To further
onfound the results of CAS, this procedure can be per-
ormed with a number of stents with different structural
esigns. As different stent designs can exhibit variable me-
hanical properties, this may lead to differential results after
AS.8 The “ideal” stent should demonstrate high flexibility
n order to navigate through difficult access anatomy and
ccommodate tortuous target vessels. The benefits of im-
roved deliverability and conformability must be balanced
ith a high resistance to particle penetration with adequate
arotid plaque coverage to prevent embolization of debris.
epending on the design, stents can be divided into those
ith an open cell or closed cell configuration. Closed cell
tents are characterized by smaller free cell areas between
truts, thus leaving smaller gaps uncovered. However, they
re less flexible than open cell stents. While it has been
stimated that all types of stents will achieve similar out-
omes in approximately 75% of all CAS procedures, the
emaining quarter requires careful preoperative screening.9
There are conflicting reports in the current literature
egarding the influence of stent cell design on CAS out-
omes. In a nonrandomized study by Bosiers et al,9 3179
atients treated with CAS in four centers with high-volume
xperience were included.5 The results showed that pa-
ients who underwent CAS with a closed cell stent experi-
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Volume 54, Number 1 Jim et al 75enced a lower (3.4% vs 1.3%; P  .02) rate of postproce-
dural events (TIA/stroke/death). This finding was even
more pronounced in symptomatic patients, with a clear
reduction (6.3% vs 1.3%; P  .0001) for the closed cell
group. In the asymptomatic population, free cell area did
not influence event rates. In another study by Schillinger et
al,6 1684 patients from 10 European centers were evalu-
ated. The combined TIA/stroke/death rate within 30 days
were 6.1% for the closed cell group compared to 4.1% for
Table IV. Risk-adjusted odds ratios for in-hospital outcom
In-hospital outcomes
Unadjusted
OPEN (vs CLOSED)
OR 95% CI
Death 0.575 0.249-1.328
Stroke 0.862 0.514-1.447
MI 0.769 0.279-2.121
TIA 0.657 0.353-1.223
TMB 0.598 0.154-2.318
Death/stroke/MI 0.774 0.501-1.194
Death/stroke/TIA 0.741 0.509-1.080
CI, Confidence interval; CLOSED, closed cell stent; MI, myocardial infarcti
transient monocular blindness.
Adjusted ORs calculated after adjusting for etiology (atherosclerosis), valvu
smoking status, baseline stenosis, and use of embolic protection. P values w
Table V. In-hospital outcomes for cell design by symptom
In-hospital outcomes
OPEN
SYMPT
(n  1633)
n (%)
ASYMP
(n  1818)
n (%)
Death, stroke, or MI 52 (3.18) 33 (1.82)
Death, stroke, or TIA 63 (3.86) 48 (2.64)
Mortality 7 (0.43) 11 (0.61)
Stroke 41 (2.51) 23 (1.27)
MI 7 (0.43) 8 (0.44)
TIA 18 (1.10) 18 (0.99)
ASYMP, Asymptomatic; CLOSED, closed cell stent;MI,myocardial infarcti
P values were based on Fisher exact test. Outcomes are defined as occurring
Table VI. In-hospital outcomes for symptomatic and asym
In-hospital outcomes
SYMP
OPEN
(n  1633)
n (%)
CLOSED
(n  427)
n (%)
Death, stroke, or MI 52 (3.18) 22 (5.15)
Death, stroke, or TIA 63 (3.86) 26 (6.09)
Mortality 7 (0.43) 6 (1.41)
Stroke 41 (2.51) 15 (3.51)
MI 7 (0.43) 4 (0.94)
TIA 18 (1.10) 8 (1.87)
ASYMP, Asymptomatic; CLOSED, closed cell stent;MI,myocardial infarcti
P values were based on Fisher exact test. Outcomes are defined as occurringthe open cell group (P  .077). Furthermore, multivariate onalyses also did not support the superiority of a specific
arotid stent cell design with respect to neurologic compli-
ations, stroke, and mortality risk. Subsequent studies with
maller patient samples have continued to show conflicting
esults.10,11 The influence of stent cell design on CAS
utcomes thus remains unclear.
Using data from the SVS-VR, outcomes on 4377 pa-
ients who underwent CAS were evaluated. In this registry,
atients treated with open cell stents had a higher incidence
Adjusted
OPEN (vs CLOSED)
value OR 95% CI P value
.1952 0.515 0.218-1.213 .1287
.5745 0.781 0.462-1.320 .3562
.6120 0.738 0.265-2.061 .5624
.1848 0.621 0.331-1.167 .1390
.4572 0.493 0.123-1.984 .3196
.2460 0.710 0.457-1.102 .1264
.1188 0.674 0.460-0.987 .0427
EN, open cell stent; OR, odds ratio; TIA, transient ischemic attack; TMB,
art disease, cardiac arrhythmia, stroke, COPD, peripheral vascular disease,
und using 2.
ogy
CLOSED
P value
SYMPT
(n  427)
n (%)
ASYMP
(n  459)
n (%) P value
.0111 22 (5.15) 6 (1.31) .0016
.0529 26 (6.09) 12 (2.61) .0124
.6373 6 (1.41) 2 (0.44) .1641
.0077 15 (3.51) 4 (0.87) .0091
1.0000 4 (0.94) 1 (0.22) .2020
.8671 8 (1.87) 6 (1.31) .5943
EN, open cell stent; SYMPT, symptomatic; TIA, transient ischemic attack.
operatively or predischarge. Rates are per patient.
matic patients by stent cell design
ASYMP
P value
OPEN
(n  1818)
n (%)
CLOSED
(n  459)
n (%) P value
.0577 33 (1.82) 6 (1.31) .5497
.0600 48 (2.64) 12 (2.61) 1.0000
.0349 11 (0.61) 2 (0.44) 1.0000
.2456 23 (1.27) 4 (0.87) .6324
.2542 8 (0.44) 1 (0.22) .6968
.2221 18 (0.99) 6 (1.31) .6074
EN, open cell stent; SYMPT, symptomatic; TIA, transient ischemic attack.
operatively or predischarge. Rates are per patient.es
P
on; OPatolptof atherosclerosis as the etiology of carotid artery stenosis.
t
w
p
l
v
a
t
t
n
n
b
a
p
t
p
F
a
A
i
t
f
t
t
s
v
s
4
c
p
W
e
p
w
o
d
c
s
c
B
i
t
d
t
t
(
h
a
i
t
n
p
d
n
C
JOURNAL OF VASCULAR SURGERY
July 201176 Jim et alThe OPEN group had a statistically significant higher prev-
alence of several major medical comorbidities. Despite this,
there were no statistically significant differences in rates of
death/stroke/MI either in-hospital or 30 days after dis-
charge between the OPEN and CLOSED groups. When
comparing symptomatology, it was not surprising to find
that symptomatic patients had a higher stroke rate in-
hospital for both the OPEN and CLOSED patients. The
higher in-hospital stroke rate for symptomatic patients in
this registry had been demonstrated in a prior report.7 At
30 days, this trend continued for the OPEN group but
symptomatology had no effect on outcomes in CLOSED
patients.With symptomatic patients, there was a statistically
significant lower rate of in-hospital mortality (0.43% vs
1.41%; P  .0349; Table VI) for the OPEN group. How-
ever, there were no differences in the rates of stroke, MI, or
TIA. The lower incidence of combined death/stroke/MI
(3.18% vs 5.15%; P .0577) for the OPEN group also had
approached, but did not reach, statistical significance. In
contrast to the in-hospital findings, the OPEN group had a
higher (5.28% vs 4.53%; P .75) rate of combined death/
stroke/MI at 30 days. There were no other differences
noted in the symptomatic subgroup. Similar to the pub-
lished literature, stent cell design had no influence on CAS
outcomes in the asymptomatic population. Overall, the
in-hospital and 30-day outcomes after CAS were not sig-
nificantly influenced by stent cell design in this study.
Several nonpatient-related factors have been shown to
play a role in the outcome of CAS. There is a significant
procedure-related learning curve and numerous studies
have demonstrated the importance of operator experi-
ence in the clinical success of CAS.12-14 Analyses of
complications of CAS have highlighted the significant
contribution of embolization originating from sources prox-
imal to the treated lesion.14-16 As neurologic events can occur
in the contralateral hemisphere as well as before crossing
the internal carotid lesion, manipulation with wires, cathe-
ters, and sheaths in a tortuous or diseased aortic arch or
Table VII. Thirty-day outcomes in OPEN versus
CLOSED patients
Thirty-day outcomes
OPEN
(n  1775)
n (%)
CLOSED
(n  547)
n (%) P value
Death, stroke, or MI 73 (4.11) 20 (3.66) .7091
Death, stroke, or TIA 92 (5.18) 27 (4.94) .9118
Mortality 25 (1.41) 10 (1.83) .5463
Stroke 45 (2.54) 9 (1.65) .2592
MI 13 (0.73) 4 (0.73) 1.0000
TIA 28 (1.58) 10 (1.83) .7004
TMB 4 (0.23) 3 (0.55) .3661
CLOSED, Closed cell stent; MI, myocardial infarction; OPEN, open cell
stent; TIA, transient ischemic attack; TMB, transient monocular blindness.
P values were based on Fisher exact test. Outcomes were defined as occur-
ring intraoperatively, predischarge, or between discharge and 30 days. Rates
are per patient.common carotid arteries can contribute to the complica- lions seen with CAS. To reduce the embolic load associated
ith femoral access, some investigators have proposed the
erformance of CAS through a cervical access. While there
acks high-quality randomized data, reports of transcer-
ical CAS, either through a percutaneous or surgical
pproach, have suggested improved outcomes compared
o the traditional transfemoral approach.17-20 While
here are nonpatient-related factors that contribute a sig-
ificant role in the outcome of CAS, stent cell design had
o statistically significant effect in this study and has not
een consistently demonstrated to play a role based on
vailable literature.
Several distinguishing features of this study merit em-
hasis. Compared to previous reports, this study includes
he largest patient sample and represents the most contem-
orary experience, with data collection beginning in 2005.
urthermore, the SVS-VR is available to all clinical facilities
nd providers in the United States wishing to participate.
s such, while the registry suffers from self-reporting bias, it
ncludes a broader collection of institutions and physicians,
hus possibly presenting data that coincides with results
ound in the “real world.” With respect to patient charac-
eristics, the proportion (47.5%) of symptomatic patients in
his study is comparable to those in the previous studies. A
ignificant difference with this study population is that the
ast majority of patients (80%) had placement of open cell
tents. In contrast, only 30% of the Bosiers et al5 series and
9% of the Schillinger et al6 series were treated with open
ell stents. Any potential effect of this discrepancy with the
revious studies is unknown.
Some limitations of this study should be discussed.
hile this is the largest patient sample to evaluate the influ-
nce of stent cell design on CAS outcomes, there remains the
ossibility of a type II error. As there are excellent results
ith both open and closed cell stents, the current number
f patients may not have enough power to detect a clinical
ifference between the two groups. With this in mind, the
urrent study suggests that the influence of stent design is
o minimal that no statistically significant differences in
linical outcomes are detectable.
While the results of this study contrast those findings by
osier et al,5 a possible explanation of this may be our
nability to differentiate the timing of neurologic complica-
ions. Verzini et al14 have demonstrated that there are
ifferential stroke risks associated with temporal phases of
he CAS procedure. In trying to explain neurologic events
hat occur in the early and late postinterventional phases
ie, after recovery of the embolic protection device), they
ypothesized that this is when the selection of stent material
nd design may play a more prominent role than the “learn-
ng-curve effect” or patient anatomy. Within the design of
he SVS-VR, there is no differentiation of the timing of the
eurologic events and as such, further analyzes are not
ossible to differentiate “procedural” and “postproce-
ural” events. While the differences remained statistically
ot significant, it is interesting to point out that the
LOSED group had a higher in-hospital event rate but a
ower rate of 30-day outcomes compared to the OPEN
c
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Volume 54, Number 1 Jim et al 77group. This may suggest a benefit of the closed cell stents in
later follow-up and that inclusion of “procedural” events
may have diluted out any potential differences between the
two groups.
There are also limitations specific to secondary data
analyses of databases such as the SVS-VR. It must be again
noted that data are self-reported by treating physicians/
institutions. The potential impact of reporting bias within
Table VIII. Risk-adjusted odds ratios for 30-day outcome
Thirty-day outcomes
Unadjusted
OPEN (vs CLOSED)
OR 95% CI
Death 0.755 0.372-1.532
Stroke 1.108 0.677-1.815
MI 1.239 0.463-3.316
TIA 0.947 0.524-1.709
TMB 0.492 0.160-1.511
Death/stroke/MI 1.032 0.691-1.541
Death/stroke/TIA 0.982 0.690-1.397
CI, Confidence interval; CLOSED, closed cell stent; MI, myocardial infarcti
transient monocular blindness.
Adjusted ORs calculated after adjusting for etiology (atherosclerosis), valvu
smoking status, baseline stenosis, and use of embolic protection. P values w
Table IX. Thirty-day outcomes for cell design by symptom
Thirty-day outcomes
OPEN
SYMPT
(n  796)
n (%)
ASYMP
(n  979)
n (%)
Death, stroke, or MI 42 (5.28) 31 (3.17)
Death, stroke, or TIA 55 (6.91) 37 (3.78)
Mortality 10 (1.26) 15 (1.53)
Stroke 29 (3.64) 16 (1.63)
MI 6 (0.75) 7 (0.72)
TIA 19 (2.39) 9 (0.92)
ASYMP, Asymptomatic; CLOSED, closed cell stent;MI,myocardial infarcti
P values were based on Fisher exact test. Outcomes are defined as occurring
patient.
Table X. Thirty-day outcomes for symptomatic and asymp
Thirty-day outcomes
SYMP
OPEN
(n  796)
n (%)
CLOSED
(n  265)
n (%)
Death, stroke, or MI 42 (5.28%) 12 (4.53%)
Death, stroke, or TIA 55 (6.91%) 15 (5.66%)
Mortality 10 (1.26%) 6 (2.26%)
Stroke 29 (3.64%) 5 (1.89%)
MI 6 (0.75%) 3 (1.13%)
TIA 19 (2.39%) 6 (2.26%)
ASYMP, Asymptomatic; CLOSED, closed cell stent;MI,myocardial infarcti
P values were based on Fisher exact test. Outcomes are defined as occurring
patient.the registry has previously been investigated and dis- oussed.7 Furthermore, the SVS-VR was not designed to
imic clinical trials involving CAS. As such, information
egarding additional clinical variables (such as target vessel
iameter, degree of tortuosity, type of embolic protection,
laque characteristics) simply was not available, and any
onfounding effects these factors may have had on the
tudy outcomes cannot be adequately analyzed. Further-
ore, as the Center for Medicare and Medicaid Services
Adjusted
OPEN (vs CLOSED)
value OR 95% CI P value
.4361 0.677 0.328-1.395 .2902
.6825 1.000 0.607-1.649 .9994
.6697 1.194 0.442-3.221 .7264
.8556 0.893 0.492-1.624 .7118
.2155 0.425 0.135-1.339 .1438
.8772 0.943 0.628-1.416 .7778
.9202 0.892 0.623-1.276 .5305
EN, open cell stent; OR, odds ratio; TIA, transient ischemic attack; TMB,
art disease, cardiac arrhythmia, stroke, COPD, peripheral vascular disease,
und using 2.
logy
CLOSED
P value
SYMPT
(n  265)
n (%)
ASYMP
(n  282)
n (%) P value
.0302 12 (4.53) 8 (2.84) .3639
.0035 15 (5.66) 12 (4.26) .5545
.6890 6 (2.26) 4 (1.42) .5343
.0093 5 (1.89) 4 (1.42) .7453
1.0000 3 (1.13) 1 (0.35) .3587
.0200 6 (2.26) 4 (1.42) .5343
EN, open cell stent; SYMPT, symptomatic; TIA, transient ischemic attack.
operatively, predischarge, or between discharge and 30 days. Rates are per
atic patients by stent cell design
ASYMP
P value
OPEN
(n  979)
n (%)
CLOSED
(n  282)
n (%) P value
.7475 31 (3.17%) 8 (2.84%) 1.0000
.5682 37 (3.78%) 12 (4.26%) .7270
.2498 15 (1.53%) 4 (1.42%) 1.0000
.2255 16 (1.63%) 4 (1.42%) 1.0000
.6984 7 (0.72%) 1 (0.35%) .6923
1.0000 9 (0.92%) 4 (1.42%) .5027
EN, open cell stent; SYMPT, symptomatic; TIA, transient ischemic attack.
operatively, predischarge, or between discharge and 30 days. Rates are pers
P
on; OPato
on; OPtom
on; OPnly require in-hospital data for CAS certification, some
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result, a significant portion of the registry does not have
data available for 30-day analysis. Finally, as with all
studies using registry data, all collected information is
retrospective in nature. However, in the absence of
randomized evidence, data from independent and verifi-
able registries still can provide valuable information
about clinical outcomes.
CONCLUSION
Although the OPEN group had a statistically signif-
icant higher prevalence of medical comorbidities, there
were no statistically significant differences in the in-
hospital or 30-day rate of death/stroke/MI. Symptom-
atic patients had higher adverse event rates compared to
the asymptomatic cohort. At this time, there is no evi-
dence of differential outcome between the use of open
and closed cell stents. However, given the low event
rates, larger population studies may be required to detect
small differences in CAS outcomes based on stent cell
design. Further randomized studies may also provide
additional insight. Until then, physicians should con-
tinue to use approved stent platforms based on criteria
other than stent cell design.
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